Sequenom Announces Enhanced Sequencing Series for MaterniT21 PLUS Test

Sequenom (NASDAQ: SQNM) announced today its wholly owned subsidiary, Sequenom Center for Molecular Medicine, doing business as Sequenom Laboratories, has launched the Enhanced Sequencing Series for its MaterniT21™ PLUS laboratory-developed test (LDT). The MaterniT21 PLUS test will begin reporting additional findings for the presence of subchromosomal microdeletions and autosomal trisomies for chromosomes 16 and 22, in addition to the previously announced additional findings for sex chromosome aneuploidies involving an abnormal number of the X or Y chromosomes. These additional findings complement the MaterniT21 PLUS test core identification of trisomies for chromosome 21, chromosome 18 and chromosome 13. With this expansion, the MaterniT21 PLUS test is the first-of-its-kind noninvasive prenatal technology (NIPT) to provide these comprehensive results from a maternal blood draw.  Sequenom Laboratories will begin reporting on these select, clinically relevant microdeletions, including  22q11.2 deletion syndrome (DiGeorge), Cri-du-chat syndrome, Prader-Willi/Angelman syndrome, 1p36 deletion syndrome, as well as trisomies 16 and 22 the last week of October.  Results from a method validation study demonstrated high performance of the MaterniT21 PLUS test (>99 percent specificity) See full press release